Society for Biomolecular Sciences to Hold Conference in Asia
News Jun 01, 2010
“A couple of years ago, the SBS board of directors made a strategic decision to expand the society’s reach internationally by bringing high quality science and networking opportunities to a global membership,” said SBS board member and conference committee Chair, John Wang. “As a first step in this strategy, SBS will establish a presence in China, where the pharmaceutical industry has experienced double-digit growth in the last decade, outpacing the country’s overall economic growth and cultivating a large community of pharmaceutical and biotechnological professionals in the process.”
Previously held in North America and Europe, SBS meetings provide a forum for the exchange of knowledge and ideas for scientists who are interested in pre- candidate drug discovery from the pharmaceutical, biotechnology and academic sectors.
In recent years, there has been significant growth within the drug-discovery community in China. Starting with the growth of the CRO sector, many pharmaceutical companies have now established research and development centers in China and there is an emerging and vibrant academic and biotechnology community elsewhere in Asia.
At the first SBS China conference, attendees will hear presentations from leading pharmaceutical companies worldwide and can take advantage of this unique opportunity to network with leaders in the field from Asia, North America and Europe. Additionally, they can explore a vendor exhibition showcasing the latest advances in the applications of novel drug-discovery technologies.
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE